Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Hematology

Survivorship and the Road Ahead

At a Glance

A stem cell transplant is the only cure for familial hemophagocytic lymphohistiocytosis (FHL), but survivors need lifelong medical monitoring. Long-term care focuses on managing late effects, supporting neurological development, monitoring growth hormones, and protecting mental health.

Successful treatment of Familial Hemophagocytic Lymphohistiocytosis (FHL) through a stem cell transplant is a monumental achievement, but it is also the beginning of a new chapter. Survivorship involves careful, long-term monitoring to manage “late effects”—health issues that can appear months or even years after the transplant is complete [1][2].

Life After Transplant: The Big Picture

A Hematopoietic Stem Cell Transplant (HSCT) is currently the only cure for FHL, as it replaces the faulty genetic “switch” with a working one [3][1]. While many children go on to live full, healthy lives, the recovery process is gradual. Research indicates that achieving complete remission before the transplant and having a successful “engraftment” (when the new cells start growing) are the strongest predictors of long-term health [4][5].

Specific Areas for Long-Term Monitoring

Because FHL and its treatments are intensive, several systems in the body require ongoing check-ups:

  • Neurological and Brain Health: FHL frequently affects the central nervous system (CNS), specifically the brain’s “white matter” [6][7]. Even after a successful transplant, survivors may face challenges with executive function, attention, or physical coordination [8]. Regular follow-ups with a neurologist and neuropsychological testing can help identify and support these needs early.
  • Hearing Health (Specific to FHL Type 5): Children with the STXBP2 mutation (FHL5) have a unique risk for hearing loss [9]. This can develop or worsen long after the initial diagnosis and transplant, so regular audiological (hearing) evaluations are a critical part of their long-term care [9].
  • Growth and Hormones: The chemotherapy and conditioning used before transplant can sometimes affect the thyroid or growth hormones [10]. A pediatric endocrinologist is often part of the long-term team to monitor your child’s growth and development.

The Psychological Toll and “Scanxiety”

The journey through FHL is emotionally exhausting for both the child and the parents. It is common to experience significant anxiety—often called “scanxiety”—leading up to follow-up appointments or blood tests [11].

  • For the Child: Survivors may need extra support in school or social settings as they transition back to “normal” life after a long period of isolation and medical trauma [11].
  • For the Parents: The hyper-vigilance required during the crisis phase can be hard to “turn off.” Many parents find it helpful to work with a therapist or join support groups specifically for rare disease or transplant families (such as those provided by the Histiocytosis Association) to process the experience [11].

While FHL is a complex and high-stakes condition, the goal of modern medicine is not just survival, but helping your child thrive. Active, lifelong partnership with a survivorship team is the best way to ensure any late effects are caught and managed early [12].

Common questions in this guide

What are the late effects of a stem cell transplant for FHL?
Late effects are health issues that emerge months or years after treatment is completed. For FHL survivors, these can include neurological challenges, growth or hormone issues, and sometimes hearing loss.
Why does my child need neurological monitoring after an FHL transplant?
FHL often impacts the central nervous system and the brain's white matter. Even after a successful transplant, survivors may experience challenges with attention, executive function, or physical coordination that benefit from early support.
Does FHL cause hearing loss?
Children with the STXBP2 mutation, known as FHL Type 5, have a unique risk for developing hearing loss. Because this can worsen long after the transplant, regular audiology check-ups are an essential part of their survivorship plan.
Why do we need to see an endocrinologist after an FHL transplant?
The chemotherapy and conditioning treatments used to prepare the body for a stem cell transplant can sometimes affect the thyroid and growth hormones. A pediatric endocrinologist will track your child's physical development to ensure any hormonal issues are addressed.
How can we cope with the anxiety of follow-up testing?
Anxiety leading up to follow-up appointments, often called 'scanxiety', is very common. Working with a therapist and joining support groups for transplant families can help both you and your child process medical trauma and navigate the transition back to normal life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our long-term schedule for monitoring neurological development and 'executive function' (attention and memory)?
  2. 2.For our child's specific mutation (e.g., FHL5), how often should we have their hearing tested?
  3. 3.Which late effects are most likely based on the specific chemotherapy and conditioning regimen my child received?
  4. 4.Can we be referred to a pediatric endocrinologist to monitor growth and hormone levels?
  5. 5.Who will be our primary contact for coordinating long-term survivorship care?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Clinical, Genetic, and Outcome Characteristics of Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis.

    Nepesov S, Yaman Y, Elli M, et al.

    Turkish archives of pediatrics 2022; (57(4)):398-405 doi:10.5152/TurkArchPediatr.2022.21314.

    PMID: 35822471
  2. 2

    Successful correction of familial hemophagocytic lymphohistiocytosis using prenatal genetic testing and preemptive hematopoietic stem cell transplantation.

    Michniacki TF, Mulcahy Levy JM, Quinones RR, Giller RH

    Bone marrow transplantation 2018; (53(2)):223-224 doi:10.1038/bmt.2017.219.

    PMID: 29035396
  3. 3

    Haploidentical hematopoietic stem cell transplantation using reduced-intensity conditioning for pediatric patients with familial hemophagocytic lymphohistiocytosis.

    Jia C, Wang B, Zhu G, et al.

    Pediatric investigation 2018; (2(4)):216-221 doi:10.1002/ped4.12096.

    PMID: 32851268
  4. 4

    Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study.

    Bergsten E, Horne A, Hed Myrberg I, et al.

    Blood advances 2020; (4(15)):3754-3766 doi:10.1182/bloodadvances.2020002101.

    PMID: 32780845
  5. 5

    Hemophagocytic Lymphohistiocytosis and Graft Failure Following Unrelated Umbilical Cord Blood Transplantation in Children.

    Noguchi M, Inagaki J

    Journal of pediatric hematology/oncology 2020; (42(6)):e440-e444 doi:10.1097/MPH.0000000000001795.

    PMID: 32287100
  6. 6

    Clinical and neuroimaging features of familial hemophagocytic lymphohistiocytosis.

    Alkaphoury MG, Mohammad SA, Farghal NBE, et al.

    Pediatric radiology 2026; (56(2)):443-454 doi:10.1007/s00247-025-06454-5.

    PMID: 41251694
  7. 7

    A Case of Familial Hemophagocytic Lymphohistiocytosis Type 4 With Involvement of the Central Nervous System Complicated With Infarct.

    Ciraci S, Ozcan A, Ozdemir MM, et al.

    Journal of pediatric hematology/oncology 2017; (39(6)):e321-e324 doi:10.1097/MPH.0000000000000886.

    PMID: 28692549
  8. 8

    Brain MRI imaging markers associated with death in children with central nervous system involvement of hemophagocytic lymphohistiocytosis.

    Ma W, Zhou L, Li W, et al.

    European radiology 2024; (34(2)):873-884 doi:10.1007/s00330-023-10147-8.

    PMID: 37624411
  9. 9

    Low-Frequency Sensorineural Hearing Loss in Familial Hemophagocytic Lymphohistiocytosis Type 5.

    Bezdjian A, Bruijnzeel H, Pagel J, et al.

    The Annals of otology, rhinology, and laryngology 2018; (127(6)):409-413 doi:10.1177/0003489418771714.

    PMID: 29776323
  10. 10

    The clinical and laboratory evaluation of familial hemophagocytic lymphohistiocytosis and the importance of hepatic and spinal cord involvement: a single center experience.

    Beken B, Aytac S, Balta G, et al.

    Haematologica 2018; (103(2)):231-236 doi:10.3324/haematol.2017.178038.

    PMID: 29146706
  11. 11

    Every Second Patient Does Not Fully Understand Written Preprocedure Information: An Explorative Study About Functional Health Literacy.

    Janmyr E, Grossmann B, Nilsson A

    Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses 2024; (39(6)):1075-1078 doi:10.1016/j.jopan.2024.02.004.

    PMID: 38958625
  12. 12

    Chronic Graft-Versus-Host-Disease-Related Polymyositis: a 17-Months-Old Child with a Rare and Late Complication of Haematopoietic Stem Cell Transplantation.

    Chinello M, Balter R, De Bortoli M, et al.

    Mediterranean journal of hematology and infectious diseases 2020; (12(1)):e2020002 doi:10.4084/MJHID.2020.002.

    PMID: 31934312

This page provides general information about FHL survivorship and transplant recovery for educational purposes. Always consult your child's transplant team and specialists to create a personalized, long-term survivorship care plan.

Get notified when new evidence is published on Familial hemophagocytic lymphohistiocytosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.